BBT-176 gets approval for Phase 1 and 2 trials by FDA

Home > Business > Industry

print dictionary print

BBT-176 gets approval for Phase 1 and 2 trials by FDA

Bridge Biotherapeutics said Monday that it has received approval from the U.S. Food and Drug Administration to start Phase 1 and 2 clinical trials for BBT-176.

BBT-176, a third-generation therapy for non-small cell lung cancer, will be tested with a small number of patients in Korea through a dose escalation study. The treatment from Bridge Biotherapeutics is separate from AstraZeneca’s Tagrisso.

BBT-176 will tested again in the United States and Korea. The studies will be used to observe safety, tolerability and anti-tumor efficacy of BBT-176 among patient groups.

The candidate substance, which was first discovered by the Korea Research Institute of Chemical Technology, was licensed to Bridge Biotherapeutics in late 2018.

By Ko Jun-tae

More in Industry

No dial tone for 2G services on LG U+ starting in June

Ironing out an air corridor took decades

Kia reinvents itself, promising 'movement that inspires'

Hanwha Energy teams up with France's Total in U.S.

Scatter Lab investigated, but not for odd messages

Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now